PE20010385A1 - UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO - Google Patents

UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO

Info

Publication number
PE20010385A1
PE20010385A1 PE2000000757A PE0007572000A PE20010385A1 PE 20010385 A1 PE20010385 A1 PE 20010385A1 PE 2000000757 A PE2000000757 A PE 2000000757A PE 0007572000 A PE0007572000 A PE 0007572000A PE 20010385 A1 PE20010385 A1 PE 20010385A1
Authority
PE
Peru
Prior art keywords
piperidin
thiophene
benzo
phenoxy
hydroxy
Prior art date
Application number
PE2000000757A
Other languages
English (en)
Inventor
Julie Kay Bush
Conrad Preston Charles Charles
Wayne Douglas Luke
Merlyn Gerard Flom
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010385A1 publication Critical patent/PE20010385A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE AL CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO (ARZOXIFENO), QUE SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS ESTROGENOS, PROGESTAGENOS TAL COMO NORETILNODREL, NORETINDRONA; INHIBIDOR DE AROMATASA, UN ANALOGO DE LHRH, UN INHIBIDOR DE LA ACETIL COLINESTERASA TAL COMO SALICILATO DE FISOSTIGMINA, CLORHIDRATO DE TACRINA, CLORHIDRATO DE DONEPEZILO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE CRISTALIZAR CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b)]TIOFENO EN TETRAHIDROFURANO. EL COMPUESTO ES UN AGONISTA/ANTAGONISTA MIXTO DE ESTROGENOS Y PUEDE SER UTIL PARA REDUCIR LOS NIVELES DE COLESTEROL, INHIBIR LA HIPERLIPIDEMIA, OSTEOPOROSIS, CANCER DE MAMA, CANCER UTERINO, ENDOMETRIOSIS, TRASTORNOS DEL SNC
PE2000000757A 1999-07-29 2000-07-31 UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO PE20010385A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14628699P 1999-07-29 1999-07-29
US14757099P 1999-08-06 1999-08-06
US14977399P 1999-08-19 1999-08-19

Publications (1)

Publication Number Publication Date
PE20010385A1 true PE20010385A1 (es) 2001-04-06

Family

ID=27386379

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000757A PE20010385A1 (es) 1999-07-29 2000-07-31 UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO

Country Status (45)

Country Link
EP (1) EP1204656A2 (es)
JP (1) JP2001064277A (es)
KR (1) KR100697177B1 (es)
CN (1) CN1138770C (es)
AR (1) AR031073A1 (es)
AT (1) AT502318A1 (es)
AU (1) AU6335600A (es)
BE (1) BE1013411A3 (es)
BR (1) BR0003209A (es)
CA (1) CA2314682A1 (es)
CO (1) CO5180570A1 (es)
CZ (1) CZ299311B6 (es)
DE (1) DE10036854A1 (es)
DK (1) DK200001151A (es)
DZ (1) DZ3060A1 (es)
FI (1) FI20001722A (es)
FR (1) FR2796944B1 (es)
GB (1) GB2352717A (es)
GR (1) GR1004084B (es)
HK (1) HK1035370A1 (es)
HR (1) HRP20000503B1 (es)
HU (1) HUP0003001A2 (es)
ID (1) ID27078A (es)
IL (1) IL137553A (es)
IT (1) IT1318660B1 (es)
LT (1) LT4790B (es)
LU (1) LU90617B1 (es)
LV (1) LV12623B (es)
MD (1) MD2336G2 (es)
MX (1) MXPA00007461A (es)
MY (1) MY128764A (es)
NL (1) NL1015821C2 (es)
NO (1) NO20003879L (es)
PE (1) PE20010385A1 (es)
PL (1) PL341749A1 (es)
PT (1) PT102502A (es)
RO (1) RO121851B1 (es)
SE (1) SE0002792L (es)
SG (1) SG91296A1 (es)
SI (1) SI20426A (es)
SV (1) SV2002000132A (es)
TR (1) TR200002206A2 (es)
TW (1) TWI276437B (es)
UA (1) UA72885C2 (es)
WO (1) WO2001009116A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1204655B1 (en) * 1999-07-29 2003-10-01 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
DZ3376A1 (fr) * 2000-05-08 2001-11-15 Lilly Co Eli Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
US20040014672A1 (en) * 2000-10-20 2004-01-22 Luke Wayne Douglas Novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
AU2002230409A1 (en) 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
JP4922163B2 (ja) * 2004-07-22 2012-04-25 イーライ リリー アンド カンパニー （ｓ）−６−（４−（２−（（３−（９ｈ−カルバゾール−４−イルオキシ）−２−ヒドロキシプロピル）アミノ）−２−メチルプロピル）フェノキシ）−３−ピリジンカルボキサミドヘミコハク酸塩の結晶質の不定比水和物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3989569B2 (ja) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー ベンゾチオフェン化合物、中間体、組成物および方法
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
ZA9710262B (en) * 1996-11-19 1999-05-13 Lilly Co Eli Process for the synthesis of benzothiophenes
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.

Also Published As

Publication number Publication date
SE0002792L (sv) 2001-01-30
NL1015821A1 (nl) 2001-01-30
PT102502A (pt) 2001-01-31
ID27078A (id) 2001-02-22
MD20000162A (en) 2001-04-30
CA2314682A1 (en) 2001-01-29
KR20010049916A (ko) 2001-06-15
CN1138770C (zh) 2004-02-18
FI20001722A (fi) 2001-01-30
BE1013411A3 (fr) 2001-12-04
IT1318660B1 (it) 2003-08-27
MY128764A (en) 2007-02-28
CN1288007A (zh) 2001-03-21
WO2001009116A3 (en) 2001-05-17
GR20000100265A (el) 2001-03-30
SE0002792D0 (sv) 2000-07-28
HUP0003001A2 (hu) 2002-04-29
SV2002000132A (es) 2002-06-07
TR200002206A2 (tr) 2001-03-21
UA72885C2 (uk) 2005-05-16
FR2796944B1 (fr) 2003-01-31
FR2796944A1 (fr) 2001-02-02
FI20001722A0 (fi) 2000-07-28
MXPA00007461A (es) 2004-07-16
ITMI20001759A0 (it) 2000-07-28
DZ3060A1 (fr) 2004-05-22
EP1204656A2 (en) 2002-05-15
CZ299311B6 (cs) 2008-06-18
LU90617B1 (fr) 2001-06-15
DE10036854A1 (de) 2001-03-01
MD2336G2 (ro) 2004-06-30
AR031073A1 (es) 2003-09-10
IL137553A0 (en) 2001-07-24
RO121851B1 (ro) 2008-06-30
AT502318A1 (de) 2007-02-15
NL1015821C2 (nl) 2002-01-03
TWI276437B (en) 2007-03-21
CZ20002716A3 (en) 2001-05-16
LT4790B (lt) 2001-05-25
HU0003001D0 (en) 2000-10-28
LV12623A (en) 2001-03-20
GB0018641D0 (en) 2000-09-13
DK200001151A (da) 2001-01-30
SG91296A1 (en) 2002-09-17
GR1004084B (el) 2002-12-11
JP2001064277A (ja) 2001-03-13
AU6335600A (en) 2001-02-19
HK1035370A1 (en) 2001-11-23
IE20000605A1 (en) 2001-04-04
HRP20000503A2 (en) 2001-06-30
KR100697177B1 (ko) 2007-03-21
MD2336F2 (en) 2003-12-31
NO20003879L (no) 2001-01-30
ITMI20001759A1 (it) 2002-01-28
LT2000076A (lt) 2001-02-26
SI20426A (sl) 2001-06-30
PL341749A1 (en) 2001-02-12
CO5180570A1 (es) 2002-07-30
BR0003209A (pt) 2001-03-20
WO2001009116A2 (en) 2001-02-08
IL137553A (en) 2005-09-25
LV12623B (en) 2001-07-20
GB2352717A (en) 2001-02-07
NO20003879D0 (no) 2000-07-28
HRP20000503B1 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
PE20010385A1 (es) UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO
PE20060853A1 (es) 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
ES2558030T3 (es) Método anticonceptivo oral multifásico de ciclo prolongado
PE20010383A1 (es) NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO
SK282188B6 (sk) Purifikovaná zlúčenina
AR022254A1 (es) Composicion de administracion oral.
FI925652A0 (fi) Foerfarande och sammansaettningar foer foerhindrande av befruktning och behandling av benigna gynekologiska stoerningar
CA2467222A1 (en) Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
HUP0100120A2 (en) Pharmaceutical compositions comprising estrogen agonists/antagonists suitable for treating conditions responsive to estrogen
WO2008124922A1 (en) 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
PA8523201A1 (es) Nueva composicion farmaceutica
DE69620241D1 (de) Gonadotropin releasing hormon- antagonisten
RU97104120A (ru) Фармацевтические композиции, содержащие производные эстра-1,3,5(10)-триена
HK1046647B (zh) 提高生育力的組合物
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
BRPI0409950A (pt) métodos e composições usando hormÈnio de liberação de hormÈnio gonadotropina
PE20080995A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen
AR029347A1 (es) Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica
PE20001563A1 (es) Antagonistas del receptor de vitronectina
GB0202635D0 (en) Formulation containing novel anti-inflammatory androstane derivative
AR035064A1 (es) 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
PE20010579A1 (es) Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos
BR0114792A (pt) Composto cristalino, anidro, não solvatado, de cloridreto de 6-hidróxi-3-(-4-[2-piperidin-1-il)-etóxi]-fenóxi)-2-(4-metóx i-fenil)-benzol[b]tiofeno (f-v), formulação farmacêutica, processo para preparar um composto, e uso de um composto
RU2010100337A (ru) ПРОИЗВОДНОЕ 17β-ЦИАНО-19-АНДРОСТ-4-ЕНА, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, КОТОРЫЕ ВКЛЮЧАЮТ ПРОИЗВОДНОЕ

Legal Events

Date Code Title Description
FC Refusal